David A. Siegel Palisade Bio, Inc. Transaction History

Two Sigma Advisers, LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 16, 2022	SELL	$0.81 - $1.51 $8,505 - $15,855	-10,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.3 - $2.96 $13,650 - $31,080	10,500 New	10,500 $14,000

Ticker PALI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,240,200
Market Cap $321M
Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzym...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.